Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
Johann S. de Bono(Royal Marsden NHS Foundation Trust), Ulrik Lassen(Rigshospitalet), Jeffrey Yachnin(Karolinska University Hospital), Kristian Windfeld(Genmab (Denmark)), Fiona Thistlethwaite(The Christie NHS Foundation Trust), Nicole Concin(Medical University of Vienna), David S. Hong(The University of Texas MD Anderson Cancer Center), Joo Ern Ang(Royal Marsden NHS Foundation Trust), James Spicer(King's College London), Brian M. Slomovitz(Mount Sinai Medical Center), Ruth Plummer(National Health Service), Robert H. Jones(Velindre NHS Trust), Dearbhaile Catherine Collins(Cork University Hospital), Srinivas Ghatta(Genmab (United States)), Martin Förster, Dorte Nielsen(Herlev Hospital), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Emma Dean(AstraZeneca (United Kingdom)), Jean-Pascal Machiels(Cliniques Universitaires Saint-Luc), Reshma Rangwala(Genmab (United States))
Cited by 228
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
|International Journal of Gynecological Cancer|2020|1.9k